Table 4.

10,000 iteration bootstrap resampling point estimates and 95% CIs for the difference in estimated effect sizes between all 24-month trial design pairs.

	SUVR no enrich, ADAS12	SUVR no enrich, ADAS13	SUVR 1.10, ADAS11	SUVR 1.10, ADAS12	SUVR 1.10, ADAS13	SUVR 1.30, ADAS11	SUVR 1.30, ADAS12	SUVR 1.30, ADAS13	SUVR 1.40, ADAS11	SUVR 1.40, ADAS12	SUVR 1.40, ADAS13
SUVR no enrich, ADAS11	−0.09 (−0.18--0.02)	−0.1 (−0.19--0.02)	0.04 (−0.5–0.35)	0.02 (−0.47–0.3)	−0.02 (−0.5–0.25)	−0.13 (−0.81–0.23)	−0.11 (−0.69–0.21)	−0.16 (−0.76–0.17)	−0.15 (−1.17–0.3)	−0.17 (−1.11–0.25)	−0.17 (−0.99–0.23)
SUVR no enrich, ADAS12		−0.01 (−0.04–0.03)	0.13 (−0.39–0.43)	0.11 (−0.36–0.38)	0.07 (−0.38–0.33)	−0.03 (−0.71–0.31)	−0.01 (−0.59–0.29)	−0.06 (−0.66–0.25)	−0.06 (−1.07–0.39)	−0.08 (−1.02–0.33)	−0.07 (−0.89–0.32)
SUVR no enrich, ADAS13			0.14 (−0.39–0.45)	0.12 (−0.36–0.4)	0.07 (−0.38–0.34)	−0.03 (−0.71–0.33)	−0.01 (−0.59–0.31)	−0.06 (−0.66–0.26)	−0.05 (−1.06–0.4)	−0.08 (−1.02–0.35)	−0.07 (−0.88–0.33)
SUVR 1.10, ADAS11				−0.02 (−0.13–0.1)	−0.06 (−0.18–0.07)	−0.17 (−0.64–0.02)	−0.14 (−0.56–0.08)	−0.19 (−0.62–0.02)	−0.19 (−0.95–0.12)	−0.21 (−0.9–0.08)	−0.2 (−0.82–0.08)
SUVR 1.10, ADAS12					−0.04 (−0.14–0.07)	−0.15 (−0.6–0.07)	−0.13 (−0.5–0.04)	−0.18 (−0.58–0.03)	−0.17 (−0.94–0.17)	−0.19 (−0.87–0.1)	−0.19 (−0.8–0.11)
SUVR 1.10, ADAS13						−0.1 (−0.54–0.11)	−0.08 (−0.45–0.12)	−0.13 (−0.49–0.02)	−0.13 (−0.89–0.22)	−0.15 (−0.83–0.16)	−0.14 (−0.73–0.14)
SUVR 1.30, ADAS11							0.02 (−0.1–0.2)	−0.03 (−0.14–0.13)	−0.03 (−0.48–0.16)	−0.05 (−0.43–0.12)	−0.04 (−0.36–0.16)
SUVR 1.30, ADAS12								−0.05 (−0.2–0.09)	−0.05 (−0.63–0.21)	−0.07 (−0.55–0.12)	−0.06 (−0.47–0.18)
SUVR 1.30, ADAS13									0 (−0.55–0.28)	−0.02 (−0.49–0.21)	−0.01 (−0.38–0.2)
SUVR 1.40, ADAS11										−0.02 (−0.15–0.12)	−0.01 (−0.12–0.26)
SUVR 1.40, ADAS12											0.01 (−0.1–0.22)

Caption: ADAS-Cog = Alzheimer's Disease Assessment Scale-Cognitive Subscale, SUVR = standardized uptake value ratio